CLAIM DETAILS
RPLE seeks to recover compensation for Canadians affected with brain and spinal tumours or lesions known as meningiomas after taking Depo-Provera.
Depo-Provera Brain Tumour Risks:
The active ingredient in Depo-Provera, medroxyprogesterone acetate, has been linked to an increased risk of developing meningiomas. A large French study was published in March 2024 finding that reproductive-aged women who used medroxyprogesterone acetate had a 5.55-fold increased risk of meningiomas. This same study also found that women taking other types of contraceptives, including oral birth control pills, were not at an increased risk.
Meningiomas are typically benign tumours that develop in tissues surrounding the brain and spinal cord. Since they can grow and put pressure on adjacent brain tissue and structures, they often require surgical or radiation treatment with the potential to cause brain injury.
The lawsuit alleges that the defendants, Pfizer Inc. and its subsidiaries, failed to ensure that Depo-Provera was safe for its ordinary use and provided no warning to consumers of this possibly life-threatening tumours, despite the company knowing about the risks for some time.
Women Diagnosed with Meningiomas After Using Depo-Provera
If you or a member of your family has suffered injuries or complications from Depo-Provera, our class action team is available to try to assist you in seeking compensation.
Complete the form below to subscribe to our database and receive all updates and notices regarding this class action.
CURRENT STATUS
This litigation is still in its early stages. The court will decide at a later date if the case will proceed as a class action.
